Biosimilars: costs and administrative burden are stopping uptake

A new industry report calls for measures to improve access to biosimilar medicines in Australia The level of uptake of biosimilar medicines in Australia is well below the average across the Organisation of Economic CO-operation and Development (OECD), says a new report that aims to galvanise efforts to improve usage of these medicines. The report